Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients
Kazuaki Chayama, Kazuo Notsumata, Masayuki Kurosaki, Ken Sato, Lino Rodrigues, Carolyn Setze, Prajakta Badri, Tami Pilot‐Matias, Regis A. Vilchez, Hiromitsu Kumada – 16 January 2015 – Approximately 2 million Japanese individuals are infected with hepatitis C virus and are at risk for cirrhosis, end‐stage liver disease, and hepatocellular carcinoma. Patients in whom interferon (IFN)/ribavirin (RBV) therapy has failed remain at risk as effective therapeutic options are limited.